Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Skin Neoplasms × Nivolumab × Clear all

Phase

Phase 2 7 Phase 1 5 Phase NA 2 Phase EARLY_PHASE1 2 Phase 4 1 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 21 Melanoma 20 Carcinoma, Renal Cell 12 Stomach Neoplasms 8 Lung Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 5 Brain Neoplasms 5 Mesothelioma 4 Kidney Neoplasms 4 Carcinoma, Hepatocellular 4 Adenocarcinoma Of Esophagus 4 Urinary Bladder Neoplasms 3 Neoplasms 3 Neoplasm Metastasis 3 Head and Neck Neoplasms 3 Various Advanced Cancer 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Mesothelioma, Malignant 2 Liver Neoplasms 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Carcinoma 2 Anus Neoplasms 2 Adenocarcinoma 2 von Hippel-Lindau Disease 1 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Thoracic Neoplasms 1

Interventions

Dacarbazine 4 cemiplimab 2 binimetinib 2 Ipilimumab 2 vitespin 1 trametinib 1 tilsotolimod 1 spartalizumab 1 pembrolizumab 1 oblimersen 1 gp100 Melanoma Antigen 1 encorafenib 1 dabrafenib 1 bempegaldesleukin 1 aldesleukin 1 Vinblastine 1 Vemurafenib 1 Tretinoin 1 Standard of Care 1 Sodium Chloride 1 Sirolimus 1 Radiotherapy 1 Radiation 1 Nivolumab 1 Interleukin-2 1 Interferon-alpha 1 Interferon alpha-2 1 Injections 1 Everolimus 1 Educational Status 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04410445 2023-04-21

PIVOT-12

Nektar Therapeutics

Phase 3 Terminated

765 enrolled 13 charts

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡